The Future of R&D in Pharmaceutical Industry in 2025

From ScenarioThinking
Revision as of 17:39, 12 September 2009 by Ruthdonners (talk | contribs)
Jump to navigation Jump to search

EMBA09 team:
Murat Akguc
Ruth Donners
Peter Friedl
Susan Liu
Eva Stjernschantz

Work under construction. In case you have any questions and comments, please do not edit these pages, but you are more than welcome to contact us.

Scenarios.



To be added

Driving forces.

Edited existing ones

• Increasing potential to grow based on new available technology
• Struggling old world economy
• Increasing Empowerment of Consumers in Healthcare System
• Continuously growing demand for new medical applications
• The increasing gap between developed, emerging and poor economies
• The increasing globalization of markets
• Power of the United Nations
• Legal Restrictions for Biotech increasing in certain countries, decreasing in others


two more will be added

Added new ones

• IP rights
• Logistics/Distribution
• Illnesses of global importance/Pandemics
• Research budget in pharmaceutical industry
• Effect of development of health care system in emerging market countries to existing pharmaceutical industry
• Unification of regulatory approval
• Competitiveness through innovation in biotechnology
• New business models for pharmaceutical industry


two more will be added

Retrieved from "https://www.scenariothinking.org/index.php?title=The_Future_of_R%26D_in_Pharmaceutical_Industry_in_2025&oldid=27630"